A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)

Trial Profile

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Duvelisib (Primary) ; Ofatumumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms DUO
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 23 Mar 2017 According to a Verastem media release, the company expects to report top-line data from this trial in mid-year 2017.
    • 30 Jun 2016 According to an Infinity Pharmaceuticals media release, the company expects to report topline data from this trial in the third quarter of 2016.
    • 28 Jun 2016 According to an Infinity Pharmaceuticals media release, the company continues to focus on filing an NDA for duvelisib with the US FDA in the fourth quarter of 2016 and plans to include data from this and a phase II trial (DYNAMO) in the application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top